Atazanavir Teva 150 mg Capsules, hard Ireland - English - HPRA (Health Products Regulatory Authority)

atazanavir teva 150 mg capsules, hard

teva b.v. - atazanavir sulfate - capsule, hard - 150 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 pi mutations). there are very limited data available from children aged 6 to less than 18 years

Atazanavir Teva 200 mg Capsules, hard Ireland - English - HPRA (Health Products Regulatory Authority)

atazanavir teva 200 mg capsules, hard

teva b.v. - atazanavir sulfate - capsule, hard - 200 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 pi mutations). there are very limited data available from children aged 6 to less than 18 years

Atazanavir Teva 300 mg Capsules, hard Ireland - English - HPRA (Health Products Regulatory Authority)

atazanavir teva 300 mg capsules, hard

teva b.v. - atazanavir sulfate - capsule, hard - 300 milligram(s) - protease inhibitors; atazanavir - protease inhibitor - atazanavir teva capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products. based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors ( 4 pi mutations). there are very limited data available from children aged 6 to less than 18 years (

Atazanavir Krka European Union - English - EMA (European Medicines Agency)

atazanavir krka

krka, d.d., novo mesto - atazanavir (as sulfate) - hiv infections - antivirals for systemic use - atazanavir krka capsules, co-administered with low dose ritonavir, are indicated for the treatment of hiv-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 pi mutations).the choice of atazanavir krka in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.

Atazanavir (Teva) New Zealand - English - Medsafe (Medicines Safety Authority)

atazanavir (teva)

teva pharma (new zealand) limited - atazanavir sulfate 170.872mg (equiv 150 mg atazanavir) - capsule - 150 mg - active: atazanavir sulfate 170.872mg (equiv 150 mg atazanavir) excipient: crospovidone gelatin indigo carmine lactose monohydrate magnesium stearate titanium dioxide - atazanavir is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

Atazanavir (Teva) New Zealand - English - Medsafe (Medicines Safety Authority)

atazanavir (teva)

teva pharma (new zealand) limited - atazanavir sulfate 227.829mg (equiv 200 mg atazanavir) - capsule - 200 mg - active: atazanavir sulfate 227.829mg (equiv 200 mg atazanavir) excipient: crospovidone gelatin indigo carmine lactose monohydrate magnesium stearate titanium dioxide - atazanavir is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

Atazanavir (Teva) New Zealand - English - Medsafe (Medicines Safety Authority)

atazanavir (teva)

teva pharma (new zealand) limited - atazanavir sulfate 341.744mg (equiv 300 mg atazanavir) - capsule - 300 mg - active: atazanavir sulfate 341.744mg (equiv 300 mg atazanavir) excipient: crospovidone gelatin indigo carmine iron oxide red iron oxide yellow lactose monohydrate magnesium stearate titanium dioxide - atazanavir is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

Atazanavir Teva Capsules Hard 150mg Malta - English - Medicines Authority

atazanavir teva capsules hard 150mg

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 150 mg - antivirals for systemic use

Atazanavir Teva Capsules Hard 200mg Malta - English - Medicines Authority

atazanavir teva capsules hard 200mg

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 200 mg - antivirals for systemic use

Atazanavir Teva Capsules Hard 300mg Malta - English - Medicines Authority

atazanavir teva capsules hard 300mg

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - atazanavir sulfate - hard capsule - atazanavir sulfate 300 mg - antivirals for systemic use